ArticleFrontiers in oncology2026
Trends and disparities in skin malignant neoplasm mortality in the United States: a 22-year trend analysis based on CDC WONDER Data (1999-2020).
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Skin malignant neoplasms are common malignancies worldwide, with epidemiological characteristics showing significant geographical and demographic disparities. This study aims to comprehensively analyze the temporal trends and demographic disparities in skin malignant neoplasm mortality among US adults from 1999 to 2020 using the CDC WONDER database. Methods: Mortality data for skin malignant neoplasms (ICD-10: C43-C44) among US adults (≥25 years) from 1999 to 2020 were obtained from the CDC's WONDER online database. Joinpoint regression analysis was used to evaluate temporal trends in age-adjusted mortality rates (AAMR), calculating annual percent change (APC) and average annual percent change (AAPC). Stratified analyses were conducted by sex, age group, race/ethnicity, geographic region, and rural-urban status. Results: Between 1999 and 2020, a total of 251,848 skin malignant neoplasm deaths were reported in the United States, with an age-adjusted mortality rate of 5.299 per 100,000 person-years. Male mortality rates (8.137 per 100,000) were significantly higher than female rates (3.157 per 100,000). The overall mortality rate showed an increasing trend from 1999 to 2014 (APC =+ 0.271%), followed by a significant decrease from 2014 to 2017 (APC=-5.292%), and remained stable from 2017 to 2020 (APC=-0.563%).Age group analysis revealed that adults aged 65 and older had the highest mortality rate (17.902 per 100,000). Regarding racial disparities, white people had significantly higher mortality rates (5.996 per 100,000) compared to Black or African American(1.291 per 100,000) and Hispanic or Latino(1.018 per 100,000). Geographically, the Southern region had the highest mortality rate (5.452 per 100,000), and rural areas (5.960 per 100,000) had higher rates than metropolitan areas (5.160 per 100,000). State-level analysis showed that Idaho, Oklahoma, West Virginia, Kentucky, and Delaware ranked highest in mortality rates nationwide. Conclusion: Skin malignant neoplasm mortality in the United States shows an overall declining trend, but significant disparities exist across demographic characteristics and geographic regions. These findings provide important evidence for developing targeted prevention strategies and resource allocation for high-risk populations. Future research should further explore potential factors behind these disparities, including socioeconomic factors, healthcare accessibility, and environmental exposures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.